



ASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING ANTIMIGRAINE TREATMENT.


M. HERNÁNDEZ SÁNCHEZ, M.D. NÁJERA PÉREZ, J.A. GUTIÉRREZ SÁNCHEZ, M.A. CARVAJAL, P. TORRANO BELMONTE, J. IBANEZ-CATURLA, L. FRUCTUOSO GONZALEZ, M. GUILLÉN DÍAZ, P. PACHECO, A. MARTINEZ OREA.

OBJETIVES

Evaluation of quality of life and self-perceived health status in migraine patients treated with erenumab or galcanezumab before administration, three months after and one year later.

MATERIALS Y METHODS

Retrospective study conducted in a hospital by administering EQ-5D-5L questionnaires.



Patients completed the visual analogue scale (VAS), graduated from 0 (worst health condition) to 10. They were analyzed globally and anonymously.

RESULTS

		INITIAL	3 MONTH	ONE YEAR
MOBILITY	Mild symptoms	76,10	55,22	28,87
	Severe symptoms	2,98	2,80	-
SELF-CARE	Mild symptoms	91,10	53,23	37,31
	Severe symptoms	2,98	2,98	0,00
ACTIVITIES OF DAILY LIVING	Mild symptoms	35,80	35,80	29,90
	Severe symptoms	22,38	13,40	-
PAIN/DISCOMFORT	Mild symptoms	-	-	-
	Severe symptoms	68,60	25,40	4,50
ANXIETY/DEPRESSION	Mild symptoms	52,20	-	23,90
	Severe symptoms	26,90	13,40	6,00

VAS scale

A median of 5 was obtained at the beginning compared to 6.25 three months later and 7 one year later.

CONCLUSIONS

- "Pain/discomfort" and "depression/anxiety" are the most affected.
- "Pain/discomfort" was the one that improved the most and "daily activities" did not improve.
- The VAS scale showed an increase in quality of life after three months by 1.25 points of median and 2 points after one year.